 |
| |
| Apr-18-18 | Reiterated |
Stifel |
Hold |
$145 → $135 |
|
| Jan-24-18 | Reiterated |
Stifel |
Hold |
$142 → $145 |
|
| Jan-12-18 | Reiterated |
Wells Fargo |
Outperform |
$155 → $160 |
|
| Jan-02-18 | Downgrade |
JP Morgan |
Overweight → Neutral |
|
|
| Oct-18-17 | Reiterated |
Stifel |
Hold |
$140 → $142 |
|
| Oct-18-17 | Reiterated |
RBC Capital Mkts |
Outperform |
$144 → $147 |
|
| Oct-18-17 | Reiterated |
Leerink Partners |
Outperform |
$150 → $165 |
|
| Oct-16-17 | Reiterated |
Jefferies |
Buy |
$157 → $160 |
|
| Oct-11-17 | Upgrade |
Jefferies |
Hold → Buy |
|
|
| Oct-09-17 | Upgrade |
Wells Fargo |
Market Perform → Outperform |
|
|
| Sep-25-17 | Initiated |
Citigroup |
Neutral |
$140 |
|
| Sep-20-17 | Downgrade |
Goldman |
Neutral → Sell |
$125 → $130 |
|
| Jul-21-17 | Downgrade |
BTIG Research |
Neutral → Sell |
$110 |
|
| Jul-21-17 | Downgrade |
Alembic Global Advisors |
Neutral → Underweight |
|
|
| Jul-20-17 | Resumed |
Credit Suisse |
Outperform |
$148 |
|
| Jul-05-17 | Reiterated |
Morgan Stanley |
Overweight |
$135 → $140 |
|
| May-18-17 | Reiterated |
Stifel |
Hold |
$124 → $128 |
|
| May-15-17 | Upgrade |
JP Morgan |
Neutral → Overweight |
|
|
| Jan-26-17 | Downgrade |
Wells Fargo |
Outperform → Market Perform |
|
|
| Jan-25-17 | Reiterated |
RBC Capital Mkts |
Outperform |
$133 → $128 |
|
|
|
| Apr-19-18 07:52PM | P&G, GE and IBM Need to Innovate; Has Starbucks' Stock Grown Ice Cold?--ICYMI TheStreet.com |
| 03:26PM | Healthcare ETFs in Focus After Johnson & Johnson Q1 Earnings Zacks |
| Apr-18-18 09:00PM | 3 Drugs That Are Moving the Needle at Johnson & Johnson Motley Fool |
| 06:11PM | After the Bell: Dow Drops 38 Points BecauseIBM Barrons.com |
| 05:10PM | Kentucky Gov. Matt Bevin slams state AG's lawsuit against J&J: 'These are political moves' CNBC |
| 01:23PM | Kentucky Governor Bevin: I'm not on board with JNJ opioid... CNBC Videos |
| 11:24AM | Kentucky accuses J&J of contributing to opioid epidemic Reuters |
| 11:07AM | IBM and J&J stocks cut 100 points from Dow industrials in early trading MarketWatch |
| 10:50AM | Kentucky accuses J&J of contributing to opioid epidemic Reuters |
| 09:11AM | Location revealed: Johnson & Johnson institute's new HQ to go in Lake Nona's Medical City American City Business Journals |
| 07:00AM | The resume of the future will tell employers who you are, and not just what youve done Quartz |
| 12:17AM | [$$] Johnson & Johnson Raises Sales Outlook The Wall Street Journal |
| Apr-17-18 07:37PM | Trump touts economy as stocks rally Fox Business Videos |
| 05:01PM | U.S. drug agency proposes rules to rein in opioid manufacturing Reuters |
| 05:00PM | What to Look for as First-Quarter Earnings Hit Around the Globe Bloomberg |
| 04:47PM | UnitedHealth and Alphabet climb; Tesla and Comerica skid Associated Press |
| 04:44PM | Wall Street rises on earnings hopes, Netflix soars Reuters |
| 04:26PM | J&J Boosts Sales Forecast On Growing Demand For Cancer Drugs Investor's Business Daily |
| 04:08PM | Dow Jumps Over 200 Points; S&P 500 and Nasdaq Also Finish Higher TheStreet.com |
| 01:12PM | J&J raises sales forecast but keeps profit outlook unchanged; shares drop Reuters |
| 01:08PM | Drug Division Drives Johnson & Johnson Morningstar |
| 01:07PM | Why Geron Corporation's Stock Is Heading Higher Today Motley Fool |
| 12:43PM | Johnson & Johnson Stock Dips Despite Q1 Earnings Beat InvestorPlace |
| 11:35AM | Johnson & Johnson (JNJ) Q1 2018 Earnings Conference Call Transcript Motley Fool |
| 11:25AM | J&J raises sales forecast but keeps profit outlook unchanged; shares drop Reuters |
| 11:02AM | Johnson & Johnson tops 1Q views on sales spike, but net dips Associated Press |
| 10:45AM | J&J Lives Up to Its Valuation -- For Now Bloomberg |
| 10:39AM | New Construction Data, Q1 Earnings In Focus Zacks |
| 10:28AM | [$$] Johnson & Johnson Raises Sales Outlook The Wall Street Journal |
| 10:25AM | Tax Day Not So Taxing (for Corporations, Housing) Zacks |
| 09:40AM | J&J (JNJ) Tops Q1 Earnings Estimates, Raises Sales Guidance Zacks |
| 09:40AM | Zytiga, Stelara Lift Johnson & Johnson's Sales Motley Fool |
| 09:38AM | Stocks to Watch: Goldman Sachs, Netflix, Amazon, Tesla, Microsoft, Roku, UnitedHealth, J&J, Walmart The Wall Street Journal |
| 09:11AM | Morning Movers: Goldman, UnitedHealth Jump on Earnings, Twitter Takes Off on Upgrade Barrons.com |
| 09:04AM | J&J raises sales forecast on strong demand for cancer drugs Reuters |
| 09:00AM | Premarket Trading: Blue Chips, Netflix Power Up; China Adds Tariffs Investor's Business Daily |
| 08:53AM | [$$] US stock futures higher as earning season picks up pace Financial Times |
| 08:37AM | Why Johnson & Johnsons (NYSE:JNJ) ROE Of 2.16% Does Not Tell The Whole Story Simply Wall St. |
| 08:06AM | Stocks making the biggest moves premarket: UNH, JNJ, GS, NFLX, ROKU, DIS & more CNBC |
| 07:52AM | Johnson & Johnson CFO Plans for a Strong Year for 2018 Bloomberg Video |
| 07:52AM | Johnson & Johnson CFO Plans for a Strong Year for 2018 Bloomberg |
| 07:49AM | Global stocks turn higher on upbeat corporate earnings Associated Press |
| 07:35AM | New Research: Key Drivers of Growth for Johnson & Johnson, Chesapeake Energy, Visa, Celgene, Adobe, and Markel Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire |
| 07:32AM | [$$] Johnson & Johnson up in pre-market as Q1 results top forecasts Financial Times |
| 07:07AM | J&J Raises Sales Forecast in Health Earnings Season Kick-Off Bloomberg |
| 06:56AM | Johnson & Johnson's stock gains after profit and revenue beat, raised outlook MarketWatch |
| 06:50AM | Johnson & Johnson CFO: Pharma business continues 'stellar... CNBC Videos |
| 06:40AM | Johnson & Johnson Reports 2018 First-Quarter Results: PR Newswire |
| 06:32AM | Pharma fuels Johnson & Johnson's first-quarter earnings beat CNBC |
| 06:32AM | Here's what to expect from Johnson & Johnson earnings CNBC |
| 06:30AM | Johnson & Johnson to Host Earnings Call ACCESSWIRE |
| Apr-16-18 07:35PM | Fed speakers and earnings from Goldman Sachs and others could influence Tuesday's market CNBC |
| 04:00PM | Pa., N.J. health systems and universities form multistate clinical trials consortium American City Business Journals |
| 01:09PM | Upcoming Earnings: Johnson & Johnson And IBM Are Scheduled To Report This Week Benzinga |
| 10:32AM | J&J Baby Powder litigation takes new focus with asbestos claims Reuters |
| 07:00AM | Medtronic's Portfolio Is Unmatched Morningstar |
| 02:21AM | J&J Baby Powder litigation takes new focus with asbestos claims Reuters |
| 01:08AM | J&J Baby Powder litigation takes new focus with asbestos claims Reuters |
| Apr-15-18 01:17PM | Is bluebird bio, Inc. a Buy on the Dip? Motley Fool |
| 10:05AM | 3 Things to Watch in the Stock Market This Week Motley Fool |
| 06:31AM | Better Buy: Eli Lilly and Company vs. Johnson & Johnson Motley Fool |
| Apr-14-18 10:21PM | [$$] US bank earnings, World Bank-IMF spring meetings Financial Times |
| 02:16PM | 3 Top Dividend Stocks to Buy in April Motley Fool |
| 07:17AM | 3 Safe Dividend Stocks for a Chaotic Market Motley Fool |
| Apr-13-18 01:56PM | Local experts talks artificial intelligence on the First Coast American City Business Journals |
| 01:30PM | 10 Best Stocks to Buy and Hold Forever InvestorPlace |
| 11:13AM | Here's Why Geron Stock Surged More Than 90% in 6 Months Zacks |
| 11:04AM | Is J&J's (JNJ) Pharma Segment Likely to Drive Q1 Earnings? Zacks |
| 10:31AM | Chardan: Assembly Biosciences Hep B Antiviral Data 'Positive,' But Undifferentiated From Competitor Johnson & Johnson Benzinga |
| 10:15AM | With A -92.14% Earnings Drop, Did Johnson & Johnson (NYSE:JNJ) Really Underperform? Simply Wall St. |
| 08:15AM | Can Johnson & Johnson Get Its Mojo Back? Motley Fool |
| 07:48AM | Why Geron Corporation Stock Popped 84% in March Motley Fool |
| Apr-12-18 05:51PM | U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report TheStreet.com |
| 01:58PM | Top ETF Picks for Your IRA Zacks |
| 12:30PM | Why Geron Corporation Stock Is on the Rise Today Motley Fool |
| 12:27PM | Get a look at Johnson & Johnson's HQ expansion in Lake Nona (RENDERINGS) American City Business Journals |
| 08:17AM | J&J (JNJ) to Begin Pharma Q1 Earnings: What's in Store? Zacks |
| 05:19AM | Ad Prices On Fox's 'The Ingraham Angle' Fall In The Wake Of Advertiser Boycott Forbes |
| Apr-11-18 05:00PM | J&J, Imerys unit must pay $117 million in New Jersey asbestos cancer case Reuters |
| 04:42PM | J&J, Imerys unit must pay $117 mln in N.J. asbestos cancer case Reuters |
| 02:58PM | Asbestos in Talc Products Verdict Means J&J, Imerys Owe Millions Bloomberg |
| 02:55PM | J&J, Imerys must pay $80 mln punitive damages in case linking cancer to asbestos in talc Reuters |
| 09:37AM | Alkermes Has Some Decisions to Make Motley Fool |
| 08:10AM | 4 Blue-Chip Stocks to Buy Ahead of Eye-Popping Earnings Zacks |
| 12:00AM | [$$] Healthcare: Cancer breakthrough leads Chinas biotech boom Financial Times |
| Apr-10-18 02:56PM | Why J&Js Fallen Stock Is Still Too Pricey Investopedia |
| 11:13AM | Google to power Georgia data center with solar energy American City Business Journals |
| 07:40AM | Wired News Johnson & Johnson to Pay Compensatory Damages over Claims Linking Cancer to Asbestos in Talc ACCESSWIRE |
| 07:34AM | Novartis and Other Drug Stocks With FDA Catalysts in April Zacks |
| Apr-09-18 07:09PM | Billionaire Ken Fishers Favorite Dividend Stocks Insider Monkey |
| 03:43PM | Glancy Prongay & Murray LLP Reminds Investors of the April 9, 2018 Deadline in the Class Action Lawsuit Against Johnson & Johnson Business Wire |
| 11:20AM | DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Johnson & Johnson And Reminds Investors To Contact The Firm ACCESSWIRE |
| 11:11AM | DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of Johnson & Johnson of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 9, 2018 JNJ ACCESSWIRE |
| 06:00AM | 3 Reasons This Clinical-Stage Biotech Is an Incredible Bargain Motley Fool |
| Apr-06-18 03:14PM | NJ Man Wins $37 Million in J&J Baby Powder Case InvestorPlace |
| 02:24PM | Stocks dive as US proposes more China tariffs; Dow falls 620 Associated Press |
| 11:29AM | APRIL 9 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Johnson & Johnson And Reminds Investors To Contact The Firm ACCESSWIRE |
| 10:36AM | MARKETS: Watch out for the 'Kudlow Put' round 2 and the Chinese tariff tantrum Yahoo Finance Video |
| 09:59AM | The Top 5 Johnson & Johnson Shareholders (JNJ) Investopedia |
| 09:27AM | 4 Drug/Biotech Stocks to Buy Ahead of World Health Day Zacks |
|
|
|
|
| Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads under the STAYFREE and CAREFREE brands, and tampons under the o.b. brand; wound care products comprising adhesive bandages under the BAND-AID brand and first aid products under the NEOSPORIN brand. The company's Pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, cardiovascular and metabolic, and pulmonary hypertension diseases. Its Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products that include blood glucose monitoring; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Stoffels Paulus | Exec VP, Chief Scientific Off | Feb 15 | Option Exercise | 90.44 | 155,342 | 14,049,130 | 357,906 | Feb 20 07:46 PM | | Stoffels Paulus | Exec VP, Chief Scientific Off | Feb 15 | Sale | 129.86 | 155,342 | 20,172,401 | 202,564 | Feb 20 07:46 PM | | Caruso Dominic J | Exec VP, Finance; CFO | Feb 09 | Option Exercise | 0.00 | 10,601 | 0 | 154,703 | Feb 13 06:54 PM | | Duato Joaquin | Exec VP, WW Chair, Pharma | Feb 09 | Option Exercise | 0.00 | 9,812 | 0 | 78,348 | Feb 13 06:54 PM | | Fasolo Peter | Exec VP, Chief HR Officer | Feb 09 | Option Exercise | 0.00 | 5,830 | 0 | 69,992 | Feb 13 06:54 PM | | Gorsky Alex | Chairman, CEO | Feb 09 | Option Exercise | 0.00 | 33,165 | 0 | 285,990 | Feb 13 06:54 PM | | PETERSON SANDRA E | Exec VP, Group WW Chairman | Feb 09 | Option Exercise | 0.00 | 11,445 | 0 | 70,205 | Feb 13 06:54 PM | | Stoffels Paulus | Exec VP, Chief Scientific Off | Feb 09 | Option Exercise | 0.00 | 13,252 | 0 | 181,655 | Feb 13 06:55 PM | | Ullmann Michael H | Exec VP, General Counsel | Feb 09 | Option Exercise | 0.00 | 5,953 | 0 | 115,257 | Feb 13 06:55 PM | | Kapusta Ronald A | Controller, CAO | Feb 09 | Option Exercise | 0.00 | 2,702 | 0 | 32,666 | Feb 13 06:55 PM | | Mesquita Jorge S. | Exec VP, WW Chair, Consumer | Feb 02 | Option Exercise | 0.00 | 32,688 | 0 | 32,688 | Feb 06 04:21 PM | | Stoffels Paulus | Exec VP, Chief Scientific Off | Oct 31 | Option Exercise | 0.00 | 75,492 | 0 | 203,142 | Nov 02 05:01 PM | | Stoffels Paulus | Exec VP, Chief Scientific Off | Jul 24 | Option Exercise | 72.54 | 102,692 | 7,449,278 | 230,342 | Jul 26 11:49 AM | | Stoffels Paulus | Exec VP, Chief Scientific Off | Jul 24 | Sale | 133.14 | 102,692 | 13,672,629 | 127,650 | Jul 26 11:49 AM | | Caruso Dominic J | Exec VP, Finance; CFO | Jul 20 | Option Exercise | 61.75 | 82,591 | 5,099,994 | 226,693 | Jul 24 11:06 AM | | Caruso Dominic J | Exec VP, Finance; CFO | Jul 20 | Sale | 136.72 | 82,591 | 11,291,478 | 144,102 | Jul 24 11:06 AM |
|
|
|
|
|
|
